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Finaly an important issue is the possibility to rechallenge
patients after a first occurrence of immune-mediated hepatitis.
The indication of a corticosteroid prophylaxis in this case
remains debated. In two patients from Gauci et al.’s series and
in three of our patients, immunotherapy was resumed without
recurrence of hepatitis, suggesting that rechallenge is a feasible
option.
At the moment several questions regarding IRAEs need to be
addressed in the search for predictive biomarkers of toxicity, the
precise pathophysiology, and the relationship between toxicity
and antitumor response.3,4 For liver immune related toxicity,
further specific questions are to identify patients who can
improve spontaneously, to search for the minimal effective dose
of corticosteroids, and to identify the patients for whom
immunotherapy can be safely reintroduced. Moreover, research
should specifically focus on liver tissue biomarkers, which can
better predict the liver severity of toxicity induced by
immune-checkpoint inhibitors and would be of great value.
We hope that these preliminary data concerning the man-
agement of immune-mediated hepatitis will be a new starting
point to re-think hepatic IRAEs, to make collective efforts in
finding the answers to the above questions and to improve
patient outcomes.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.jhep.2018.04.
019.
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JOURNAL 
OF HEPATOLOGYReal-world data on antiviral treatments for hepatitis
C virus infections: Can we define intention to treat
or per protocol analyses?To the Editor:
We read with interest a recent study that used real-world (i.e.
observational) data from the German Hepatitis C-Registry.1
The 12-week sustained virologic response (SVR) was compared
between 8- and 12-week regimens of ledipasvir/sofosbuvir. The
authors used classifications of intention to treat (ITT) and per
protocol to define eligibility of patients for their analyses.1
One classification of ITT defined eligibility as patients who com-
pleted treatment with either the 8- or 12-week ledipasvir/sofos-
buvir regimen (SVR 85%). The second classification of ITT
defined eligibility as patients who initiated and completed
either the 8- or 12-week ledipasvir/sofosbuvir regimen (SVR
95%). Per protocol defined eligibility as patients who initiated
and completed treatment, adhered to treatment throughout the
duration, and had SVR status assessed 12 weeks post-treatment
completion (SVR 98%). Nevertheless, such use of the terms ITT
and per protocol have undue popularity in real-world studies of
direct-acting antivirals (DAAs).1–3
ITT and per protocol are approaches for statistical analysis of
randomized controlled trials (RCTs) and pertain to treatment
status.4 Neither approach is used to define eligibility and nei-
ther approach is directly applicable to real-world studies. ITT
involves analyzing outcomes for RCT participants based on the
treatment to which they were randomized, regardless of adher-
ence to the allocated treatment.4 ITT preserves the balance of
known and unknown confounders between comparison groupsKeywords: Hepatitis C virus; Direct-acting antivirals; Observational; Real-world;
Intention to treat; Per protocol.Journal of Hepatology 2018 vol. 69 j 547–558 551
(i.e. exchangeability), which is the key benefit of randomization
for causal inference. In contrast, real-world studies have an
inherent risk of confounding by indication, which no form of
statistical adjustment can completely resolve.5 Per protocol
involves analyzing outcomes for participants based on adher-
ence with the allocated treatment, which addresses the issue
of treatment misclassification.4 The potential reduction in treat-
ment misclassification comes with the trade-off of breaking ran-
domization; a per protocol analysis effectively converts the trial
to a quasi-experimental study.4
The approach by Buggisch et al.1 and others is incompatible
with ITT or per protocol definitions and raises serious concerns
about overestimated SVR in real-world studies. To facilitate
awareness of biasing mechanisms, the four possible types of
HCV-infected patients who initiated DAAs in any real-world
study regardless of treatment duration are illustrated (Fig. 1).
The distribution of these four patient types across regimens
(e.g. 8- or 12-weeks) ultimately determines the observed SVR
incidence. Given that we cannot rely on randomization to desig-
nate treatment status as in an RCT and the planned treatment
duration (8 weeks or 12 weeks) was not recorded in the
registry,1 we must rely on exposure to treatment for eligibility.
Treatment duration could have been modified based on an
intermediate measure of response, which exacerbates the
potential for confounding by indication. Nevertheless, we
emphasize that all four patient types would be eligible for the
analysis. Type 1 and 2 patients were followed through treat-
ment completion and 12-week SVR assessment, and SVR was
achieved by type 1 but not type 2 patients. Type 3 patients com-
pleted treatment, but the SVR status was unknown because of
loss to follow-up (e.g. some barrier to care), whereas type 4
patients were lost to follow-up before completing treatment
(e.g. side-effects or other reasons for discontinuation) and SVR
status was also unknown. Buggisch et al.1 excluded type 4
patients because of missing SVR status, but these patients were
eligible albeit unlikely to achieve SVR. In addition, the main
analyses (labeled ‘‘per protocol”) excluded type 3 patients
because of missing SVR status despite SVR being possible but
unknown. Such exclusion relies on the unrealistic assumption
that excluded cases were missing completely at random.6
Non-random exclusion of patients based on outcome status
leads to a selected population of patients who completed
treatment and had a high probability of SVR. Even the lowest
estimate of SVR reported in the study (85%) may be an
overestimate.
Observational analogues of ITT and per protocol can be esti-
mated using a counterfactual framework,7,8 but these methods
also require addressing the problem of missing outcome data.
Given well-known problems with complete case analysis,6 the
challenge is how to handle patients with missing outcome data
because of loss to follow-up. This challenge applies to RCTs and
real-world studies, and no consensus has been established
about the best approach. A simple approach is to designate
worst-case and best-case scenarios, where none of the individ-
uals with missing SVR status would have achieved SVR or all of
the individuals would have achieved SVR, respectively.9 The
range of estimates based on these designations can be informa-
tive unless extensively missing SVR status is present.9 More
sophisticated approaches include multiple imputation and
inverse probability weighting, but these approaches are not nec-
essarily superior in all scenarios.9,10
We conclude that the interpretation of favorable response
with 8- or 12-week treatment and the observed small differ-
ences between these regimens is problematic. Some limitations
of real-world data cannot be overcome. Sensitivity analyses and
cautious interpretation are encouraged.
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Fig. 1. Distribution of patient types and follow-up in real-world studies of
direct-acting antivirals for hepatitis C virus infections. (The diamond at 12-
week follow-up for patient type 1 represents sustained virologic response
(SVR) and the circle for type 2 represents no SVR. Patient types without these
symbols indicate loss to follow-up.)
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Reply to: ‘‘Real-world data on antiviral treatments
for hepatitis C virus infections: Can we define intention
to treat or per protocol analyses?”
To the Editor:
We thank Ojha and Steyerberg1 for making a valid point regard-
ing our manuscript. Indeed, defining analysis populations of
real-life observational studies as intention-to-treat or per proto-
col is problematic, as this wording may suggest a higher compa-
rability to clinical trials than exists.
In principle, even refined methods for adjusting confounders
and minimizing bias cannot fully resolve the inherent problem
of confounders in such trials. In our paper the wording (inten-
tion-to-treat and per protocol) was chosen for comparability
with similar previous observational studies2 and a lot of effort
was made to make the definitions transparent by illustrating
them in a figure and mentioning them several times in the
article.
Furthermore, the results were carefully discussed and, over-
all, highly comparable with those from clinical trials. Therefore,
potential overestimation of sustained response rates as illus-
trated and discussed in the letter by Ojha and Steyerberg seems
to be a limited problem in our article discussing this real-world
data.
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